[The rational diagnostic of cholangiocarcinoma].

Cholangiocarcinoma (CC) is a rare malignant tumour arising from cholangiocytes, and its prognosis is usually unfavourable, mostly as a result of late diagnosis of the tumour. The current incidence of cholangiocarcinoma in the Czech Republic is 1.4/100,000 inhabitants per year; in less than 30 % of patients with CC, one of the known risk factors can be identified, most frequently, primary sclerosing cholangitis. Only patients with early diagnosed and surgically amenable cholangiocarcinoma are likely to have a longer survival time; in their case, survival for more than five years has been achieved in 20 % to 40 %. From the perspective of the need for early diagnosis of CC, a significant part is played by imaging and histopathologic evaluation; the early diagnostic significance of oncomarkers is limited. The rational early diagnosis of CC consists in effective use of differentiated advantages of different imaging modalities - MRI with DSA appears to be the optimal method, endosonography is a sensitive method for the identification of malignancy in the hepatic hilum or distal common bile duct, MRCP (magnetic resonance cholangiopancreatography) is used to display pathological changes in the biliary tree, ERCP (endoscopic retrograde cholangiopancreatography) allows material removal for histopathological examination. Other new approaches are also beneficial, such as IDUS - intraductal ultrasonography of biliary tract or SPY-GLASS, enabling examination of the bile ducts by direct view with the possibility of taking targeted biopsies. Sensitivity and specificity of histology and cytology can be increased by using the molecular cytogenetic FISH method, i.e. fluorescence in situ by hybridization, with a specificity of 97 %.

[1]  S. Pereira,et al.  Update on the Management of Cholangiocarcinoma , 2014, Digestive Diseases.

[2]  G. Gores,et al.  Molecular Pathogenesis of Cholangiocarcinoma , 2014, Digestive Diseases.

[3]  Ondřej Urban MUDr,et al.  Cholangiopankreatoskopie pomocí SpyGlass TM direct visualization system: Seznámení s metodou a první vlastní zkušenosti , 2013 .

[4]  S. Hattori,et al.  Clinicopathologic Analysis of Combined Hepatocellular-Cholangiocarcinoma According to the Latest WHO Classification , 2013, The American journal of surgical pathology.

[5]  H. Thomas,et al.  Guidelines for the diagnosis and treatment of cholangiocarcinoma: an update , 2012, Gut.

[6]  B. Petersen,et al.  Single-operator cholangioscopy in patients requiring evaluation of bile duct disease or therapy of biliary stones (with videos). , 2011, Gastrointestinal endoscopy.

[7]  G. Gores,et al.  Clinical diagnosis and staging of cholangiocarcinoma , 2011, Nature Reviews Gastroenterology &Hepatology.

[8]  H. El‐Serag,et al.  Risk factors for cholangiocarcinoma , 2011, Hepatology.

[9]  G. Gores,et al.  New staging system and a registry for perihilar cholangiocarcinoma , 2011, Hepatology.

[10]  M. Marini,et al.  Magnetic resonance cholangiography: past, present and future: a review. , 2010, European review for medical and pharmacological sciences.

[11]  H. Thomas,et al.  Polychlorinated biphenyls in bile of patients with biliary tract cancer. , 2009, Chemosphere.

[12]  K. Lindor,et al.  Utility of serum tumor markers, imaging, and biliary cytology for detecting cholangiocarcinoma in primary sclerosing cholangitis , 2008, Hepatology.

[13]  I. Endo,et al.  Intrahepatic cholangiocarcinoma , 2014, Radiopaedia.org.

[14]  Jae Seung Kim,et al.  Clinical Role of 18F-FDG PET-CT in Suspected and Potentially Operable Cholangiocarcinoma: A Prospective Study Compared With Conventional Imaging , 2008, The American Journal of Gastroenterology.

[15]  B. Petersen,et al.  Prospective Evaluation of Advanced Molecular Markers and Imaging Techniques in Patients With Indeterminate Bile Duct Strictures , 2008, The American Journal of Gastroenterology.

[16]  S. Taylor-Robinson,et al.  Epidemiology, risk factors, and pathogenesis of cholangiocarcinoma. , 2008, HPB : the official journal of the International Hepato Pancreato Biliary Association.

[17]  B. Petersen,et al.  Immunoglobulin G4-associated cholangitis: clinical profile and response to therapy. , 2008, Gastroenterology.

[18]  P. Selby,et al.  Circulating markers of biliary malignancy: opportunities in proteomics? , 2008, The Lancet. Oncology.

[19]  J. Leblanc,et al.  EUS-guided FNA of proximal biliary strictures after negative ERCP brush cytology results. , 2006, Gastrointestinal endoscopy.

[20]  B. Weynand,et al.  Endoscopic ultrasound guided fine needle aspiration in biliary and pancreatic diseases: pitfalls and performances. , 2004, Acta gastro-enterologica Belgica.

[21]  H. El‐Serag,et al.  The epidemiology of cholangiocarcinoma. , 2004, Seminars in liver disease.

[22]  K. McGlynn,et al.  Rising incidence of intrahepatic cholangiocarcinoma in the United States: a true increase? , 2004, Journal of hepatology.

[23]  H. Thomas,et al.  Guidelines for the diagnosis and treatment of cholangiocarcinoma: consensus document , 2002, Gut.

[24]  A. Bergquist Cholangiocarcinoma in primary sclerosing cholangitis , 2001 .

[25]  H. Thomas,et al.  Increase in mortality rates from intrahepatic cholangiocarcinoma in England and Wales 1968–1998 , 2001, Gut.

[26]  T. Patel Increasing incidence and mortality of primary intrahepatic cholangiocarcinoma in the United States , 2001, Hepatology.

[27]  G. Gores,et al.  The utility of CA 19-9 in the diagnoses of cholangiocarcinoma in patients without primary sclerosing cholangitis , 2000, American Journal of Gastroenterology.

[28]  Å. Danielsson,et al.  A 3-year prospective study on serum tumor markers used for detecting cholangiocarcinoma in patients with primary sclerosing cholangitis. , 1999, Journal of hepatology.

[29]  P. Hytiroglou,et al.  Differential diagnosis of hepatocellular nodular lesions. , 1998, Seminars in diagnostic pathology.

[30]  W. Palmas,et al.  Polysomy and p16 deletion by fluorescence in situ hybridization in the diagnosis of indeterminate biliary strictures. , 2012, Gastrointestinal endoscopy.

[31]  F. Bosman,et al.  WHO Classification of Tumours of the Digestive System , 2010 .

[32]  H. Uhlig Hepatologie , 2009, Kinder- und Jugendmedizin.

[33]  F. Vleggaar,et al.  High lifetime risk of cancer in primary sclerosing cholangitis. , 2009, Journal of hepatology.

[34]  M. D'Angelica,et al.  18F-fluorodeoxyglucose positron emission tomography influences management decisions in patients with biliary cancer. , 2008, Journal of the American College of Surgeons.

[35]  G. Gores Cholangiocarcinoma: Current concepts and insights , 2003, Hepatology.

[36]  S. Hesse,et al.  Positron emission tomography with [(18)F]fluoro-2-deoxy-D-glucose for diagnosis and staging of bile duct cancer. , 2001, Hepatology.

[37]  G. Gores,et al.  Hepatobiliary malignancy. , 1998, Clinics in liver disease.

[38]  E. Fishman,et al.  Intrahepatic cholangiocarcinoma: the role of imaging in detection and staging. , 1997, Critical reviews in diagnostic imaging.